Contribution of the Inflammasome to Radiation Response in Pancreatic Cancer

NIH RePORTER · NIH · K22 · $162,000 · view on reporter.nih.gov ↗

Abstract

PROJECT SUMMARY/ABSTRACT The central theme of my postdoctoral fellowships has been to investigate mechanisms by which myeloid cells are recruited and activated to promote inflammation and immunosuppression during cancer. Chronic inflammation is a recognized hallmark of carcinogenesis and my research focus is to identify critical inflammatory pathways for combinatorial therapeutic strategies, such that the immune system can be harnessed for antitumor immunity. My current research focus is on pancreatic cancer, which is largely resistant to chemotherapy, radiation therapy (RT), and immune checkpoint blockade. RT elicits an immunogenic cell death whereby resident and recruited leukocytes respond to damage-associated molecular patterns (DAMPs) released by dying cells. Macrophages are central mediators of this response and recognize DAMPs via innate adjuvant sensors, including the toll-like receptor (TLR)/MyD88 pathway. Specificity in this pathway is regulated by expression of various NFB subunits that homo- or heterodimerize to drive transcriptional pathways involved in immune activation or immune suppression. My current work is to understand how Mertk-dependent upregulation of NFB p50 regulates macrophage immune suppression post-RT, and suppresses local antitumor immunity by rewiring macrophage response to adjuvant signals through MyD88 signaling. This proposal extends on these findings to test the central hypothesis that inflammasome activation in tumor- associated macrophages restricts RT-induced antitumor CD8+ T cell responses in pancreatic cancer. As the first step of inflammasome activation, MyD88 signaling regulates transcription of IL1 and IL18 while the second step involves additional activation of inflammasome receptors by factors released by dying cells in response to RT. Our preliminary data implicate inflammasome activation in macrophages as a critical mechanism regulating immunosuppression following RT. Thus, we aim to (1) determine the functional significance of inflammasome activation in RT-mediated tumor clearance and (2) identify inflammasome signatures and phenotypes in macrophages responding to RT and determine whether this signature correlates with poor outcomes in patients. Studies utilizing lineage-specific knockout mice will identify the cell types in which inflammasome activation occurs and its functional consequences on regulating CD8+ T cell responses in response to RT. My long-term career goal is to become an independent investigator studying dominant immune mechanisms regulating cancer development and how certain aspects of innate immunity impart barriers to effective therapeutic strategies, including both traditional cytotoxic and immune-based therapies. During the K22 award period I plan to gain additional training to expand my skill set in bioinformatics, statistics, lab management, and communication skills, and to develop my independent research program so that I may establish a record of independent research proje...

Key facts

NIH application ID
10215738
Project number
1K22CA251643-01A1
Recipient
PROVIDENCE PORTLAND MEDICAL CENTER
Principal Investigator
Terry R Medler
Activity code
K22
Funding institute
NIH
Fiscal year
2022
Award amount
$162,000
Award type
1
Project period
2022-02-01 → 2025-01-31